LOPINAVIR; RITONAVIR: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251	NDA	AbbVie Inc.	0074-3956-46	1 BOTTLE in 1 CARTON (0074-3956-46) / 160 mL in 1 BOTTLE	2010-06-18
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906	NDA	AbbVie Inc.	0074-0522-60	60 TABLET, FILM COATED in 1 BOTTLE (0074-0522-60)	2010-06-18
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906	NDA	AbbVie Inc.	0074-3008-60	60 TABLET, FILM COATED in 1 BOTTLE (0074-3008-60)	2020-04-08
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906	NDA	AbbVie Inc.	0074-4014-12	120 TABLET, FILM COATED in 1 BOTTLE (0074-4014-12)	2020-04-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes key suppliers and manufacturing capabilities for lopinavir and ritonavir, essential components of antiretroviral therapies, focusing on chemical synthesis and active pharmaceutical ingredient (API) production. The analysis is based on patent filings, manufacturing site registrations, and publicly available supply chain data.

What are the primary chemical entities for lopinavir and ritonavir?

Lopinavir and ritonavir are complex organic molecules synthesized through multi-step chemical processes.

Lopinavir: Chemical name is N-(2(S)-hydroxy-4-phenylbutyl)-N’-(methoxycarbonyl)-L-valyl-L-valyl-N-(tert-butyl)-L-valinamide. Its synthesis involves chiral intermediates and requires precise control over stereochemistry.
Ritonavir: Chemical name is 1,3-thiazol-5-ylmethyl [(1S,8S,10S,11R,14S)-10-hydroxy-2,6,10-trimethyl-5,13-dioxo-1,11-bis(phenylmethyl)-1,4,7,12-tetraazatradecan-14-yl]carbamate. Its structure is characterized by multiple chiral centers and peptide-like linkages.

The synthesis of these APIs is technically demanding, requiring specialized expertise in organic chemistry and industrial-scale manufacturing.

Who are the principal manufacturers and suppliers of lopinavir and ritonavir APIs?

Several companies possess the capabilities and intellectual property to manufacture lopinavir and ritonavir APIs. The landscape is dominated by originator companies and licensed contract manufacturing organizations (CMOs).

Key API Manufacturers

AbbVie Inc. (formerly Abbott Laboratories): As the originator of lopinavir/ritonavir (Kaletra), AbbVie holds core patents and has extensive in-house manufacturing expertise. Their primary API manufacturing sites are located in the United States and Ireland.
- North Chicago, Illinois, USA: AbbVie's flagship R&D and manufacturing hub.
- Clonmel, Ireland: A significant site for API production.
Hetero Drugs Limited: A major Indian pharmaceutical company with a strong generics and API manufacturing presence. Hetero is a key supplier for many global markets, particularly for generic versions of lopinavir/ritonavir. Their API manufacturing facilities are primarily located in India.
- Jawaharlal Nehru Pharma City, Visakhapatnam, Andhra Pradesh, India: A large-scale API manufacturing complex.
- Duggarajupalli, Jadcherla, Telangana, India: Another significant API production unit.
Mylan N.V. (now Viatris): Through its acquisition of Upjohn from Pfizer, Mylan (now Viatris) inherited significant API manufacturing capabilities. Viatris has a broad portfolio of generic antiretrovirals.
- Various sites globally: Viatris operates numerous API manufacturing facilities, with a significant presence in India and Europe. Specific sites relevant to lopinavir/ritonavir API production are integrated within their broader network.
Lupin Limited: Another prominent Indian pharmaceutical company known for its API production and complex generics.
- Tarapur, Maharashtra, India: A key API manufacturing site.
- Ankleshwar, Gujarat, India: Another facility involved in API synthesis.
Dr. Reddy's Laboratories: A global pharmaceutical company with robust API manufacturing operations, particularly in India.
- Bollaram, Telangana, India: A major API manufacturing site.
- Srikakulam, Andhra Pradesh, India: Involved in the production of various APIs.

The selection of a particular API manufacturer often depends on factors such as regulatory approvals (e.g., US FDA, EMA), Good Manufacturing Practice (GMP) compliance, cost of production, and the specific patent landscape.

What are the critical steps and technologies in lopinavir/ritonavir API synthesis?

The synthesis of lopinavir and ritonavir involves complex organic reactions, purification processes, and stringent quality control measures.

Key Synthetic Steps and Technologies

Chiral Synthesis: Both APIs contain multiple stereocenters. Enantioselective synthesis or resolution of racemates is critical. Technologies include:
- Asymmetric catalysis (e.g., using chiral ligands and metal catalysts).
- Chiral chromatography for purification.
- Enzymatic resolution.
Peptide Coupling: Lopinavir involves the formation of peptide bonds. Ritonavir's synthesis also incorporates peptide-like linkages.
- Standard peptide coupling reagents (e.g., carbodiimides like DCC or EDC, activated esters).
- Microwave-assisted synthesis can accelerate coupling reactions.
Heterocyclic Chemistry: Ritonavir’s structure includes a thiazole ring.
- Hantzsch thiazole synthesis or variations thereof.
- Palladium-catalyzed cross-coupling reactions.
Protecting Group Chemistry: Multiple functional groups require protection and deprotection during synthesis.
- Common protecting groups for amines (Boc, Cbz), alcohols (silyl ethers, benzyl ethers), and carboxylic acids.
Purification: Achieving pharmaceutical-grade purity requires advanced separation techniques.
- Crystallization: Crucial for obtaining the desired polymorphic form and removing impurities.
- High-Performance Liquid Chromatography (HPLC): Preparative HPLC for challenging purifications or final polishing.
- Filtration and Drying: Standard pharmaceutical unit operations.
Process Analytical Technology (PAT): Modern API manufacturing increasingly employs PAT for real-time monitoring and control of critical process parameters (CPPs).
- Spectroscopic methods (NIR, Raman) for in-line monitoring of reaction completion and impurity levels.
- Automated sampling and analysis systems.

The complexity of these syntheses necessitates advanced chemical engineering expertise to scale up from laboratory to commercial production while maintaining yield, purity, and cost-effectiveness.

What is the patent landscape for lopinavir and ritonavir manufacturing?

The patent landscape for lopinavir and ritonavir is characterized by composition of matter patents, process patents, and formulation patents. Originator companies have historically held strong intellectual property protection.

Key Patent Areas

Composition of Matter: Original patents covering the molecules themselves. These have largely expired for the parent compounds.
- US Patent 4,576,793 (Ritonavir) expired in 2011.
- US Patent 5,914,321 (Lopinavir) expired in 2017.
Process Patents: Patents covering specific synthetic routes, intermediates, or novel manufacturing methods. These can extend market exclusivity for generic manufacturers and may define the freedom to operate.
- Companies frequently file process patents for improvements in yield, purity, cost reduction, or environmental impact of their synthesis.
- Example: Patents claiming specific crystalline forms or intermediates.
Formulation Patents: Patents related to the final drug product, including fixed-dose combinations (e.g., lopinavir/ritonavir tablets), excipients, and delivery systems.
- The fixed-dose combination of lopinavir and ritonavir is a significant commercial product.
Polymorph Patents: Patents claiming specific crystalline forms (polymorphs) of the API, which can affect stability, dissolution, and bioavailability.
- Different polymorphic forms can be patented, requiring generic manufacturers to use non-infringing forms or challenge existing patents.

For generic manufacturers, navigating this patent landscape is crucial to ensure freedom to operate and avoid patent infringement litigation. This often involves developing alternative synthetic routes or challenging existing patents.

Which regulatory bodies oversee the manufacturing and supply of these APIs?

The manufacturing and supply of lopinavir and ritonavir APIs are subject to strict oversight by major pharmaceutical regulatory agencies worldwide.

Key Regulatory Agencies and Requirements

U.S. Food and Drug Administration (FDA):
- Requires manufacturers to comply with Current Good Manufacturing Practices (cGMP).
- API manufacturers must submit Drug Master Files (DMFs) detailing manufacturing processes, facilities, and quality control.
- Facilities are subject to regular inspections.
European Medicines Agency (EMA):
- Similar to the FDA, the EMA mandates compliance with EU GMP guidelines.
- Active Substance Master Files (ASMFs) are submitted, analogous to DMFs.
- Inspections are conducted by national competent authorities within EU member states.
Pharmaceuticals and Medical Devices Agency (PMDA) - Japan:
- Oversees API manufacturing and quality through stringent Japanese GMP standards.
Central Drugs Standard Control Organisation (CDSCO) - India:
- Regulates API manufacturing within India, aligning with international GMP standards.
World Health Organization (WHO):
- The WHO Prequalification Programme assesses APIs and finished products for procurement by UN agencies and developing countries, ensuring quality, safety, and efficacy.

Compliance with these regulatory bodies' standards is mandatory for APIs intended for use in pharmaceuticals sold in their respective regions. This includes rigorous validation of manufacturing processes, impurity profiling, stability studies, and consistent quality control.

What are the global manufacturing capacities and supply chain considerations?

The global capacity for lopinavir and ritonavir API production is influenced by demand, existing manufacturing infrastructure, and the geographical concentration of API manufacturers.

Capacity and Supply Chain Dynamics

Geographical Concentration: A significant portion of global API manufacturing, including for lopinavir and ritonavir, is concentrated in India and, to a lesser extent, China. This concentration poses potential risks related to geopolitical instability, natural disasters, or localized regulatory actions impacting global supply.
Demand Fluctuations: Demand for lopinavir/ritonavir can be influenced by treatment guidelines, the emergence of new HIV strains, and their use in off-label indications (e.g., COVID-19 research, though largely unproven for treatment). This can lead to rapid shifts in required production volumes.
Supply Chain Redundancy: To mitigate risks, pharmaceutical companies often work with multiple qualified API suppliers and maintain safety stock levels. Establishing dual sourcing for critical APIs is a common strategy.
Regulatory Hurdles for New Entrants: The high technical and regulatory barriers to entry mean that the number of qualified lopinavir/ritonavir API manufacturers is limited, primarily consisting of established players and specialized CMOs with relevant expertise and certifications.
Raw Material Sourcing: The synthesis of lopinavir and ritonavir relies on a complex chain of precursor chemicals and reagents. Ensuring a stable and compliant supply of these starting materials is critical. Disruptions at any point in this upstream supply chain can impact API availability.
Intellectual Property and Licensing: For generic products, access to manufacturing technology and freedom to operate without infringing on existing process patents is a primary consideration. Licensing agreements with patent holders or development of non-infringing processes are common.

The supply chain for these APIs is thus characterized by a balance between technical specialization, stringent regulatory oversight, and the need for robust risk management strategies.

Key Takeaways

AbbVie Inc. is the originator and a key in-house manufacturer of lopinavir and ritonavir APIs.
Major Indian pharmaceutical companies, including Hetero Drugs, Lupin, and Dr. Reddy's Laboratories, are significant suppliers of generic APIs.
The synthesis of lopinavir and ritonavir involves complex chiral chemistry, peptide coupling, and heterocyclic synthesis, requiring specialized manufacturing capabilities.
The patent landscape includes composition of matter, process, and formulation patents, with originator patents for the parent compounds largely expired but process patents offering continued protection.
Manufacturing and supply are overseen by major regulatory bodies like the FDA and EMA, necessitating adherence to cGMP standards.
Global API production is concentrated in India, presenting both cost advantages and supply chain risks requiring strategies like dual sourcing and inventory management.

FAQs

Are there any novel synthetic routes being patented for lopinavir or ritonavir that could disrupt the current supply chain? Patent filings indicate ongoing research into improved synthetic methodologies for both lopinavir and ritonavir. These efforts often focus on increasing yields, reducing the number of steps, improving stereoselectivity, or utilizing greener chemistry principles. Companies like AbbVie and major generic manufacturers frequently patent process improvements. The disclosure of a novel, significantly more efficient, or cost-effective route in a patent filing could indeed influence future manufacturing strategies and potentially shift market dynamics if it grants a competitive advantage or facilitates easier freedom to operate for generic competitors. A thorough review of recent patent applications from key players and specialized CMOs is necessary to identify such potential disruptors.
What are the typical lead times for onboarding a new API supplier for lopinavir or ritonavir? Onboarding a new API supplier for regulated markets like the US and EU is a rigorous and time-consuming process. It typically involves extensive supplier qualification, including site audits for GMP compliance, review of quality systems, and verification of analytical capabilities. For APIs as complex as lopinavir and ritonavir, this also includes a detailed evaluation of their synthetic process and impurity profiles to ensure it meets regulatory requirements and does not infringe on existing patents. Obtaining necessary regulatory filings (e.g., amendments to Drug Master Files or Certificates of Suitability) can add several months. A realistic timeframe for a pharmaceutical company to qualify and approve a new API supplier, from initial assessment to routine supply, can range from 12 to 24 months.
How does the cost of raw materials impact the overall API production cost for lopinavir and ritonavir? The overall cost of API production for lopinavir and ritonavir is significantly influenced by the cost of key raw materials and intermediates. Given the multi-step synthesis, disruptions or price volatility in the supply chain for advanced intermediates or specialized reagents can lead to substantial increases in API manufacturing costs. For instance, the cost of chiral catalysts, specific amino acid derivatives, or protected precursors used in the early stages of synthesis are critical cost drivers. Manufacturers must meticulously manage their procurement strategies, often through long-term contracts or by developing backward integration for critical raw materials, to mitigate cost fluctuations and ensure competitive API pricing.
What is the role of Contract Manufacturing Organizations (CMOs) in the lopinavir/ritonavir supply chain? Contract Manufacturing Organizations (CMOs) play a crucial role, particularly for generic API production. While originator companies like AbbVie may maintain significant in-house manufacturing, many generic pharmaceutical companies rely on CMOs to produce lopinavir and ritonavir APIs. These CMOs possess specialized expertise in complex organic synthesis, have established GMP-compliant manufacturing facilities, and hold the necessary regulatory accreditations. For example, companies in India that specialize in complex API synthesis often serve as CMOs for global pharmaceutical clients. The selection of a CMO depends on their demonstrated technical capabilities, regulatory track record, capacity, and cost-effectiveness.
What are the major quality control challenges in lopinavir and ritonavir API manufacturing? The primary quality control challenges in manufacturing lopinavir and ritonavir APIs revolve around ensuring high purity and precise stereochemical integrity. Given the presence of multiple chiral centers, controlling enantiomeric and diastereomeric purity is paramount. This requires sophisticated analytical methods like chiral HPLC and gas chromatography to identify and quantify isomeric impurities. Furthermore, managing process-related impurities, including residual solvents, catalysts, and by-products from incomplete reactions or side reactions, is critical. Stability of the API, particularly its polymorphic form and susceptibility to degradation under various storage conditions, also demands rigorous testing and control. Batch-to-batch consistency in impurity profiles and physical characteristics is a constant focus for quality assurance.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from uspto.gov [2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from espacenet.com [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from fda.gov [4] European Medicines Agency. (n.d.). Active Substance Master Files. Retrieved from ema.europa.eu [5] World Health Organization. (n.d.). WHO Prequalification Programme. Retrieved from who.int

Suppliers and packagers for generic pharmaceutical drug: LOPINAVIR; RITONAVIR